ResearcherMimetas (Netherlands)No recent work listed
Karla C. S. Queiroz
Matched on ORCID iD 0000-0002-5205-5682; OpenAlex author ID A5109050912. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 4, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers
Papers 7
- A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Last author DOI 10.1038/s41420-023-01334-z↗
- The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model. Last author DOI 10.3389/fimmu.2023.1155085↗
- Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening. First author DOI 10.3389/fcell.2021.761807↗
- Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Co-author DOI 10.1002/ijc.28726↗
- Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. First author DOI 10.1002/path.4411↗
- Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. First author DOI 10.1111/jth.12361↗
- mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. First author DOI 10.1200/jco.2010.32.7825↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marlene Geyer · 3 shared papers, 2021–2023 · strength 0.74
- Paper Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening. DOI 10.3389/fcell.2021.761807↗
- Paper The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model. DOI 10.3389/fimmu.2023.1155085↗
- Paper A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. DOI 10.1038/s41420-023-01334-z↗
- Vincenzo Corbo · 1 shared paper, 2023 · strength 0.24
- Sabrina L. D’Agosto · 1 shared paper, 2023 · strength 0.24
- Daniel Schreyer · 1 shared paper, 2023 · strength 0.22
- Christian P. Pilarsky · 1 shared paper, 2023 · strength 0.22
- Dick J. Richel · 4 shared papers, 2011–2014 · strength 0.17
- Paper Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic … DOI 10.1002/path.4411↗
- Paper Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. DOI 10.1111/jth.12361↗
- Paper Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. DOI 10.1002/ijc.28726↗
- C. Arnold Spek · 4 shared papers, 2011–2014 · strength 0.17
- Paper Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic … DOI 10.1002/path.4411↗
- Paper Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. DOI 10.1111/jth.12361↗
- Paper Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. DOI 10.1002/ijc.28726↗
- Kun Shi · 3 shared papers, 2013–2014 · strength 0.14
- Paper Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic … DOI 10.1002/path.4411↗
- Paper Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. DOI 10.1111/jth.12361↗
- Paper Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. DOI 10.1002/ijc.28726↗
- Johanna W. Wilmink · 1 shared paper, 2014 · strength 0.04
- JanWillem Duitman · 1 shared paper, 2014 · strength 0.04
- Heinz‐Josef Klümpen · 1 shared paper, 2011 · strength 0.02
- G. Johan A. Offerhaus · 1 shared paper, 2011 · strength 0.02
- Roeland F. de Wilde · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.